J Korean Soc Radiol.  2012 May;66(5):427-435. 10.3348/jksr.2012.66.5.427.

Percutaneous Cryotherapy for Inoperable Lung Malignancy

• Park EH
• Jin GY
• Han YM
• Lee YC
• Kwon KS

• KMID: 1439445
• DOI: http://doi.org/10.3348/jksr.2012.66.5.427

Abstract

PURPOSE
To evaluate the therapeutic efficacy of percutaneous cryotherapy for inoperable patients with malignant pulmonary nodules.
MATERIALS AND METHODS
We enrolled 14 patients (7 males, 7 females, average age 68.8 years) who had inoperable lung malignancy in this study from August 2006 through July 2009. We evaluated the therapeutic efficacy of cryotherapy for complete or incomplete ablation by follow-up chest CT. Using Kaplan-Meier statistical methods, we estimated the survival of patients who had undergone cryotherapy and we investigated post-cryotherapy complications.
RESULTS
Five of the 14 patients underwent complete ablation (35.7%), while 9 of 14 patients underwent incomplete ablation (64.3%). The change in mean size before procedure and at last follow-up CT in the complete and incomplete ablation were as follows: 13.2 +/- 7.6 mm --> 3.8 +/- 2.7 mm, and 18.1 +/- 6.2 mm --> 33.7 +/- 17.9 mm, respectively. The median survival of patients in the complete and the incomplete groups were 51.5 months and 24 months, respectively. One patient developed a small pneumothorax, which resolved spontaneously. Two patients developed hemoptysis after the procedure, which was controlled within a day.
CONCLUSION
Percutaneous cryotherapy may be an effective and safe therapeutic method for inoperable patients with malignant pulmonary nodules.

MeSH Terms

Cryotherapy
Female
Follow-Up Studies
Hemoptysis
Humans
Lung
Lung Neoplasms
Male
Pneumothorax
Survival Rate
Thorax
Treatment Outcome

Reference

1. American Cancer Society. Cancer facts and figures 2007. 2007. Atlanta, GA: American Cancer Society.

2. Parvez T, Allam AR, Iskandrani A, Khan MA. Present trends in the treatment of advanced non small-cell lung cancer. J Coll Physicians Surg Pak. 2003. 13:483–490.

3. Downey RJ. Surgical management of lung cancer. J Thorac Imaging. 1999. 14:266–269.

4. Qiao X, Tullgren O, Lax I, Sirzén F, Lewensohn R. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer. 2003. 41:1–11.

5. Mitchell JB, Johnson DH, Turrisi AT. Lung cancer: principles and practice. 1996. Philadelphia: Lippincott-Raven;481–494.

6. Gravante G. Thermal ablation for unresectable liver tumours, time to move forward? World J Gastrointest Surg. 2010. 2:1–5.

7. Jin GY, Lee JM, Lee YC, Han YM, Lim YS. Primary and secondary lung malignancies treated with percutaneous radiofrequency ablation: evaluation with follow-up helical CT. AJR Am J Roentgenol. 2004. 183:1013–1020.

8. Pennathur A, Abbas G, Gooding WE, Schuchert MJ, Gilbert S, Christie NA, et al. Image-guided radiofrequency ablation of lung neoplasm in 100 consecutive patients by a thoracic surgical service. Ann Thorac Surg. 2009. 88:1601–1606. discussion 1607-1608.

9. Wolf FJ, Grand DJ, Machan JT, Dipetrillo TA, Mayo-Smith WW, Dupuy DE. Microwave ablation of lung malignancies: effectiveness, CT findings, and safety in 50 patients. Radiology. 2008. 247:871–879.

10. Cheetham P, Truesdale M, Chaudhury S, Wenske S, Hruby GW, Katz A. Long-term cancer-specific and overall survival for men followed more than 10 years after primary and salvage cryoablation of the prostate. J Endourol. 2010. 24:1123–1129.

11. Rosenberg MD, Kim CY, Tsivian M, Suberlak MN, Sopko DR, Polascik TJ, et al. Percutaneous cryoablation of renal lesions with radiographic ice ball involvement of the renal sinus: analysis of hemorrhagic and collecting system complications. AJR Am J Roentgenol. 2011. 196:935–939.

12. McWilliams JP, Yamamoto S, Raman SS, Loh CT, Lee EW, Liu DM, et al. Percutaneous ablation of hepatocellular carcinoma: current status. J Vasc Interv Radiol. 2010. 21:8 Suppl. S204–S213.

13. Wang H, Littrup PJ, Duan Y, Zhang Y, Feng H, Nie Z. Thoracic masses treated with percutaneous cryotherapy: initial experience with more than 200 procedures. Radiology. 2005. 235:289–298.

14. Ahmed A, Littrup P. Percutaneous cryotherapy of the thorax: safety considerations for complex cases. AJR Am J Roentgenol. 2006. 186:1703–1706.

15. Kawamura M, Izumi Y, Tsukada N, Asakura K, Sugiura H, Yashiro H, et al. Percutaneous cryoablation of small pulmonary malignant tumors under computed tomographic guidance with local anesthesia for nonsurgical candidates. J Thorac Cardiovasc Surg. 2006. 131:1007–1013.

16. Maiwand MO, Asimakopoulos G. Cryosurgery for lung cancer: clinical results and technical aspects. Technol Cancer Res Treat. 2004. 3:143–150.

17. Sandison GA, Loye MP, Rewcastle JC, Hahn LJ, Saliken JC, McKinnon JG, et al. X-ray CT monitoring of iceball growth and thermal distribution during cryosurgery. Phys Med Biol. 1998. 43:3309–3324.

18. Gillams AR. Liver ablation therapy. Br J Radiol. 2004. 77:713–723.

19. Deygas N, Froudarakis M, Ozenne G, Vergnon JM. Cryotherapy in early superficial bronchogenic carcinoma. Chest. 2001. 120:26–31.

20. Callstrom MR, York JD, Gaba RC, Gemmete JJ, Gervais DA, Millward SF, et al. Research reporting standards for image-guided ablation of bone and soft tissue tumors. J Vasc Interv Radiol. 2009. 20:1527–1540.

21. Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD 3rd, Dupuy DE, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology. 2005. 235:728–739.

22. Niu L, Wang J, Zhou L, Wu B, Mu F, Li H, et al. [Complications of cryoablation in 644 lung cancer patients and its treatment]. Zhongguo Fei Ai Za Zhi. 2010. 13:832–834.

23. Chan VO, McDermott S, Malone DE, Dodd JD. Percutaneous radiofrequency ablation of lung tumors: evaluation of the literature using evidence-based techniques. J Thorac Imaging. 2011. 26:18–26.

24. Curley SA, Marra P, Beaty K, Ellis LM, Vauthey JN, Abdalla EK, et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg. 2004. 239:450–458.

25. Shimada S, Hirota M, Beppu T, Matsuda T, Hayashi N, Tashima S, et al. Complications and management of microwave coagulation therapy for primary and metastatic liver tumors. Surg Today. 1998. 28:1130–1137.

26. Belfiore G, Moggio G, Tedeschi E, Greco M, Cioffi R, Cincotti F, et al. CT-guided radiofrequency ablation: a potential complementary therapy for patients with unresectable primary lung cancer--a preliminary report of 33 patients. AJR Am J Roentgenol. 2004. 183:1003–1011.

27. Maiwand MO. Cryotherapy for advanced carcinoma of the trachea and bronchi. Br Med J (Clin Res Ed). 1986. 293:181–182.

28. Izumi Y, Oyama T, Ikeda E, Kawamura M, Kobayashi K. The acute effects of transthoracic cryoablation on normal lung evaluated in a porcine model. Ann Thorac Surg. 2005. 79:318–322. discussion 322.

29. Brace CL, Hinshaw JL, Laeseke PF, Sampson LA, Lee FT Jr. Pulmonary thermal ablation: comparison of radiofrequency and microwave devices by using gross pathologic and CT findings in a swine model. Radiology. 2009. 251:705–711.

30. Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics. 2005. 25:Suppl 1. S69–S83.

31. Pua BB, Thornton RH, Solomon SB. Ablation of pulmonary malignancy: current status. J Vasc Interv Radiol. 2010. 21:8 Suppl. S223–S232.

32. Gillams A. Tumour ablation: current role in the kidney, lung and bone. Cancer Imaging. 2009. 9 Spec No A:S68–S70.

33. Rose SC. Radiofrequency ablation of pulmonary malignancies. Semin Respir Crit Care Med. 2008. 29:361–383.